S. 3763: ALS Better Care Act

Summary of the ALS Better Care Act

The ALS Better Care Act is proposed legislation that aims to expand Medicare coverage for individuals diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The bill seeks to address the unmet medical needs of ALS patients and improve their access to essential healthcare services.

Key Provisions

• Coverage of ALS-Related Services: The bill amends the Social Security Act to include coverage for specific ALS-related services under Medicare starting January 1, 2027. These services include:
  • Specialized physician or nurse practitioner support
  • Occupational therapy
  • Speech pathology support
  • Physical therapy
  • Dietary support
  • Respiratory support
  • Registered nurse support
  • Coordination of durable medical equipment
• Payment System for ALS-Related Services: The bill establishes a payment system for these services that ensures providers receive adequate compensation.
  • The payment for ALS-related services would start at $800 in 2027, with future adjustments based on cost increases related to these services.
  • No cost-sharing will be required for ALS-related services, meaning patients will not have to pay out-of-pocket for these services under Medicare.
• Support for Telehealth: The legislation recognizes the importance of telehealth in providing timely access to ALS care, especially for patients in rural areas or those with limited mobility.
• Clinical Trials: The bill highlights the need for improved funding and resources for ALS clinical trials, which are essential for developing new treatments. A report will be required to address challenges in administering and staffing these trials.
• Regular Reporting: The Secretary of Health and Human Services will be required to submit periodic reports that evaluate the impact of the legislation and assess the adequacy of service provisions related to ALS.

The overall aim of the ALS Better Care Act is to enhance the quality of care for ALS patients, reduce wait times for essential services, and foster innovation and research in ALS treatment.

Relevant Companies

• AMGN - Amgen: A biopharmaceutical company involved in the development of treatments for neurological diseases, including ALS.
• REGN - Regeneron Pharmaceuticals: A company that conducts research and development in the field of neurodegenerative diseases and may be impacted by increased demand for ALS therapies.
• SNY - Sanofi: Engages in multiple therapeutic areas including neurology and may see changes in market demand related to ALS treatments.